
Topic
Manufacturing Capacity
Drug substance, fill-finish, CDMO bottlenecks, inspections, tech transfer, and capacity as a commercial constraint.

Policy· June 11, 2026 · 12 min read
By Ran Chen#FDA Approval#Drug Pricing#Supply Chain

Policy· June 10, 2026 · 9 min read
Drug recalls by the numbers: 17,683 events, 80% Class II, and a sterility crisis

Approvals· June 10, 2026 · 10 min read
The FDA approval engine: 29,135 applications, 78% generics, and a BLA surge
By Ran Chen#FDA Approval#Generic Entry#Biosimilars

Policy· June 10, 2026 · 9 min read
What's in short supply: 1,146 shortages, two-thirds injectable, and an anesthesia crisis
By Ran Chen#Supply Chain#FDA Approval#Drug Pricing

Manufacturing· June 10, 2026 · 9 min read
Who supplies the world's essential medicines: 1,139 WHO-PQ products, 59% from India

Manufacturing· June 9, 2026 · 6 min read
The commercial ecosystem behind cell & gene therapy: ASGCT 2026 exhibitors mapped

Deals· June 9, 2026 · 6 min read
Biotech's two big shows compared: BIO 2026 vs ASGCT 2026

Pipeline· June 8, 2026 · 11 min read
Botulinum toxin biosimilar pathway: the 351(k) race to challenge Botox
By Ran Chen#Biosimilars#FDA Approval#BLA Approval

Global· June 8, 2026 · 11 min read
South Korea MFDS biosimilar reform 2026: what US launch teams need to know
By Ran Chen#Biosimilars#Regulatory#FDA Approval

Manufacturing· May 22, 2026 · 13 min read